William Blair Maintains Cellebrite(CLBT.US) With Buy Rating
Cellebrite DI: Strategic Focus on Inseyets Platform and Complementary Applications Drive Buy Rating With Over 20% Upside Potential
Cellebrite DI Is Maintained at Overweight by JP Morgan
Cellebrite DI Analyst Ratings
J.P. Morgan Maintains Cellebrite(CLBT.US) With Buy Rating, Raises Target Price to $24
TD Cowen Maintains Cellebrite(CLBT.US) With Buy Rating, Raises Target Price to $25
Craig-Hallum Maintains Cellebrite(CLBT.US) With Buy Rating
J.P. Morgan Maintains Cellebrite(CLBT.US) With Buy Rating, Raises Target Price to $22
Lake Street Maintains Cellebrite(CLBT.US) With Buy Rating, Raises Target Price to $21
Craig-Hallum Maintains Cellebrite(CLBT.US) With Buy Rating, Announces Target Price $24
Cellebrite DI Is Maintained at Buy by Needham
Cellebrite DI Analyst Ratings
William Blair Maintains Cellebrite(CLBT.US) With Buy Rating
Needham Maintains Cellebrite(CLBT.US) With Buy Rating, Raises Target Price to $21
Cellebrite DI: Strong Performance and Promising Outlook Justify Buy Rating Despite Leadership Transition Concerns
Craig-Hallum Maintains Cellebrite(CLBT.US) With Buy Rating
J.P. Morgan Remains a Buy on Cellebrite DI (CLBT)
Craig-Hallum Maintains Cellebrite(CLBT.US) With Buy Rating
BofA Securities Maintains Cellebrite(CLBT.US) With Buy Rating
Craig-Hallum Maintains Cellebrite(CLBT.US) With Buy Rating